Startseite>>Peptides>>Goserelin acetate

Goserelin acetate

Katalog-Nr.GC36180

Goserelinacetat (ICI-118630-Acetat), ein Decapeptid-Analogon des Gonadotropin-Releasing-Hormons (GnRH/LHRH), fungiert als GnRH-Agonist.

Products are for research use only. Not for human use. We do not sell to patients.

Goserelin acetate Chemische Struktur

Cas No.: 145781-92-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
135,00 $
Auf Lager
5mg
64,00 $
Auf Lager
10mg
93,00 $
Auf Lager
50mg
324,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com


Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Goserelin acetate (ICI 118630 acetate) is an injectable gonadotropin releasing hormone superagonist (GnRH agonist).IC50 value:Target: GnRH agonistGoserelin is used to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. It may also be used in the treatment of male-to-female transsexuals and is favoured above other anti-androgens in some countries, such as the UK. It is available as a 1-month depot and a long-acting 3-month depot. Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner.

Bewertungen

Review for Goserelin acetate

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Goserelin acetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.